1. Home
  2. ALZN vs APM Comparison

ALZN vs APM Comparison

Compare ALZN & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alzamend Neuro Inc.

ALZN

Alzamend Neuro Inc.

HOLD

Current Price

$1.02

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Logo Aptorum Group Limited

APM

Aptorum Group Limited

HOLD

Current Price

$0.99

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALZN
APM
Founded
2016
2010
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
8.0M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
ALZN
APM
Price
$1.02
$0.99
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$28.00
N/A
AVG Volume (30 Days)
179.6K
89.0K
Earning Date
03-11-2026
10-03-2025
Dividend Yield
N/A
N/A
EPS Growth
22.99
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.65
52 Week High
$8.22
$4.47

Technical Indicators

Market Signals
Indicator
ALZN
APM
Relative Strength Index (RSI) 25.85 51.58
Support Level N/A $0.71
Resistance Level $2.59 $1.11
Average True Range (ATR) 0.21 0.11
MACD -0.08 0.02
Stochastic Oscillator 2.96 32.21

Price Performance

Historical Comparison
ALZN
APM

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Share on Social Networks: